Key Points
- Insider sale: Executive Jonathan Zalevsky sold 3,867 shares on January 20 at an average price of $35.67 for about $137,936, cutting his holding by 15.33% to 21,354 shares (valued ≈ $761,697).
- Company and market context: Nektar beat recent quarterly EPS estimates (loss of $1.85 vs. -$2.85) and revenue, but remains unprofitable with negative margins and ROE; the stock trades in a wide 52‑week range ($6.45–$66.92), has a market cap of ≈ $743M, and a consensus rating of "Moderate Buy" with an average price target of $111.83.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 3,867 shares of the business's stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total value of $137,935.89. Following the transaction, the insider owned 21,354 shares of the company's stock, valued at $761,697.18. The trade was a 15.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Jonathan Zalevsky also recently made the following trade(s):
- On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The stock was sold at an average price of $54.28, for a total transaction of $62,801.96.
Nektar Therapeutics Stock Performance
Shares of NASDAQ NKTR opened at $36.53 on Friday. Nektar Therapeutics has a 52-week low of $6.45 and a 52-week high of $66.92. The stock has a market cap of $743.02 million, a P/E ratio of -4.58 and a beta of 1.31. The firm has a 50 day moving average price of $48.85 and a 200 day moving average price of $44.40.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.85) by $1.00. The company had revenue of $11.79 million during the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. Analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have weighed in on NKTR. BTIG Research lifted their price target on shares of Nektar Therapeutics from $100.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, December 16th. Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, November 16th. HC Wainwright increased their price target on Nektar Therapeutics from $120.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday, December 16th. Citigroup assumed coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They set a "buy" rating and a $102.00 price target on the stock. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Nektar Therapeutics in a research note on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $111.83.
Check Out Our Latest Analysis on NKTR
Institutional Trading of Nektar Therapeutics
A number of hedge funds have recently modified their holdings of NKTR. AQR Capital Management LLC boosted its holdings in shares of Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock worth $2,463,000 after buying an additional 2,807,595 shares during the period. Vanguard Group Inc. lifted its position in Nektar Therapeutics by 30.0% during the third quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company's stock worth $53,978,000 after acquiring an additional 219,155 shares during the last quarter. Farallon Capital Management LLC bought a new stake in shares of Nektar Therapeutics during the third quarter worth approximately $45,008,000. Two Sigma Investments LP grew its position in shares of Nektar Therapeutics by 446.9% in the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company's stock valued at $24,708,000 after purchasing an additional 354,842 shares during the last quarter. Finally, 22NW LP increased its stake in shares of Nektar Therapeutics by 126.6% during the third quarter. 22NW LP now owns 331,115 shares of the biopharmaceutical company's stock worth $18,840,000 after purchasing an additional 185,000 shares during the period. Institutional investors and hedge funds own 75.88% of the company's stock.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.
Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
